Slovak Marilyn L
Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA 20151, USA.
Clin Lab Med. 2011 Dec;31(4):699-724, x. doi: 10.1016/j.cll.2011.08.009.
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells characterized by complex genetic aberrations and heterogeneous outcomes. Over the past 25 years, cytogenetic analysis has played a key role in the diagnosis and management of MM. This article reviews the conventional cytogenetics, molecular cytogenetics, and genomic diagnostics of MM and highlights a few recent clinical trials that demonstrate the impact of genetic risk stratification on the treatment of this plasma cell malignancy.
多发性骨髓瘤（MM）是一种终末分化浆细胞的恶性肿瘤，其特征为复杂的基因畸变和异质性的预后。在过去25年里，细胞遗传学分析在MM的诊断和管理中发挥了关键作用。本文综述了MM的传统细胞遗传学、分子细胞遗传学和基因组诊断，并重点介绍了一些近期的临床试验，这些试验证明了基因风险分层对这种浆细胞恶性肿瘤治疗的影响。
